COMMUNIQUÉS West-GlobeNewswire

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
18/03/2026
DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the [...]
SRx Health Solutions Hedges Investments in Cryptocurrency and Emerging Markets for Volatility Protection
18/03/2026
The Company will update shareholders in the near future on the proposed timing to close the EMJX transaction NORTH PALM BEACH, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) ( [...]
Prenetics to Participate in the 38th Annual ROTH Conference
18/03/2026
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today [...]
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
18/03/2026
WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno- [...]
VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland
18/03/2026
— The lowered pricing structure is now available for 101.82 EUR per bottle at pharmacies throughout Finland AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company [...]
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
18/03/2026
NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen [...]
VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland
18/03/2026
— The lowered pricing structure is now available for 798,86 DKK per bottle at pharmacies throughout Denmark AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company [...]
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full [...]
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
18/03/2026
43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice. Veterinarians are seen as the most trusted source of pet health advice. “Small acts of [...]
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18/03/2026
ORION CORPORATION PRESS RELEASE 18 March 2026 at 10:00 EET Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership Orion Corporation (“Orion Pharma”) and CMI - Martti Ahtisaari [...]
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18/03/2026
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional [...]
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
18/03/2026
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures [...]
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18/03/2026
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing [...]
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
18/03/2026
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en [...]
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s [...]
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
18/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV- [...]

Pages